| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|---|---|---|---|---|---|---|
| L1 | 12 | ("3282986"\|"4988733"\|"6235786"\|"6294573"\|"6423690").PN. | USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 11:15 |
| L2 | 2 | "20050119343" | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 13:14 |
| L3 | 559 | "4444784" | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 13:18 |
| L4 | 56 | "4582915" | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 13:36 |
| L5 | 241 | 560/256 | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:06 |
| L6 | 3400929 | Ca calcium | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:07 |
| L7 | 3886 | simvastatin | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:07 |
| L8 | 160 | 7 near10 6 | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:08 |
| L9 | 128 | 7 near6 6 | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:08 |
| L10 | 118 | 7 near5 6 | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:16 |

| | | | | | | |
|---|---|---|---|---|---|---|
| L11 | 42 | 8 not 10 | US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT | OR | ON | 2005/10/24 14:17 |

```
=> d his

     (FILE 'HOME' ENTERED AT 11:08:21 ON 24 OCT 2005)

     FILE 'REGISTRY' ENTERED AT 11:08:33 ON 24 OCT 2005
L1            1 S SIMVASTATIN/CN

     FILE 'CAPLUS' ENTERED AT 11:08:53 ON 24 OCT 2005
L2         2707 S L1
L3      1229331 S CALCIUM OR CA
L4          289 S L2 AND L3
L5           14 S L2 (6A) L3
L6           18 S L2(10A) L3
L7           24 S L2 (L) L3

=> s l6 not l7
L8            0 L6 NOT L7

=> d l7 17

L7   ANSWER 17 OF 24  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2000:645976  CAPLUS
DN   133:222503
TI   Preparation and formulation of crystalline simvastatin acid calcium salt
     for pharmaceutical use as a HMG-CoA reductase and CYP3A inhibitor
IN   Tillyer, Richard D.; Reider, Paul J.; Grabowski, Edward J. J.; Xu, Feng
PA   Merck and Co., Inc., USA
SO   PCT Int. Appl., 59 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2000053566        A1    20000914    WO 2000-US2627          20000202
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2365869            AA    20000914    CA 2000-2365869         20000202
     EP 1163203            A1    20011219    EP 2000-904644          20000202
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002539108         T2    20021119    JP 2000-604007          20000202
     AU 764048             B2    20030807    AU 2000-26370           20000202
     EP 1036783            A1    20000920    EP 2000-301864          20000307
     EP 1036783            B1    20030521
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     AT 240934             E     20030615    AT 2000-301864          20000307
     PT 1036783            T     20030829    PT 2000-301864          20000307
     ES 2198253            T3    20040201    ES 2000-301864          20000307
     JP 2000281626         A2    20001010    JP 2000-63739           20000308
     US 2005119343         A1    20050602    US 2004-981866          20041105
PRAI US 1999-123247P       P     19990308
     US 1999-264745        A     19990309
     WO 2000-US2627        W     20000202
     US 2000-651463        B2    20000830
```

```
     US 2000-656109        B2     20000906
     US 2000-660956        B1     20000913
     US 2002-293153        B1     20021113
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s amorphous
L9      247255 AMORPHOUS

=> d his

     (FILE 'HOME' ENTERED AT 11:08:21 ON 24 OCT 2005)

     FILE 'REGISTRY' ENTERED AT 11:08:33 ON 24 OCT 2005
L1            1 S SIMVASTATIN/CN

     FILE 'CAPLUS' ENTERED AT 11:08:53 ON 24 OCT 2005
L2         2707 S L1
L3      1229331 S CALCIUM OR CA
L4          289 S L2 AND L3
L5           14 S L2 (6A) L3
L6           18 S L2(10A) L3
L7           24 S L2 (L) L3
L8            0 S L6 NOT L7
L9       247255 S AMORPHOUS

=> s ca salt
        743431 CA
        749889 SALT
L10       6892 CA SALT
                 (CA(W)SALT)

=> s calcium salt
        739276 CALCIUM
        749889 SALT
L11      10549 CALCIUM SALT
                 (CALCIUM(W)SALT)

=> s l10 or l11
L12      16338 L10 OR L11

=> s l2 and l9
L13           5 L2 AND L9

=> d tot cbib abs

L13  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2005 ACS on STN
2005:120698   Document No. 142:225773  Controlled release dosage forms
     containing cholesteryl ester transfer protein inhibitors and immediate
     release of HMG-CoA reductase inhibitors.  Curatolo, William John; Friesen,
     Dwayne Thomas; Sutton, Steven C. (Pfizer Products Inc., USA).  PCT Int.
     Appl. WO 2005011634 A1 20050210, 199 pp.  DESIGNATED STATES: W:  AE, AG,
     AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU,
     CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
     IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
     MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
     SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
     YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES,
     FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG,
     TR.  (English).  CODEN: PIXXD2.  APPLICATION: WO 2004-IB2457 20040721.
     PRIORITY: US 2003-PV492407 20030804.
AB   A dosage form comprises a cholesteryl ester transfer protein inhibitor in
     a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the
```

dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release of the cholesteryl ester transfer protein inhibitor. A solubility-improved from of torcetrapib was prepared by forming a solid **amorphous** dispersion of torcetrapib in hydroxypropyl Me cellulose acetate succinate (HPMCAS). The dispersion was prepared by spray-drying a solution containing 4.0% torcetrapib, 12.0% HPMCAS-MG (AQUOT-MG), and 84% acetone. The solution was spray-dried by using a pressure spray nozzle.

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

2004:550886 Document No. 141:94364 Compositions of cholesteryl ester transfer protein inhibitors and HMG-COA reductase inhibitors. Babcock, Walter Christian; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore (Pfizer Products Inc., USA). PCT Int. Appl. WO 2004056395 A1 20040708, 168 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-IB6170 20031218. PRIORITY: US 2002-PV435328 20021220.

AB A composition comprises (1) a solid **amorphous** adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor is disclosed. The solid **amorphous** adsorbate provides concentration enhancement of the CETP inhibitor relative to a control composition consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability. A solid **amorphous** adsorbate was prepared from torcetrapib, fumed silica (Cab-O-Sil), and mixed with granules containing atorvastatin hemicalcium trihydrate, calcium carbonate, microcryst. cellulose, croscarmellose sodium, polysorbate, hydroxypropyl cellulose, and pregelatinized starch, and then pressed into 150 mg compacts. The resulting compacts each contained 32 mg torcetrapib and 3.2 mg atorvastatin trihydrate hemicalcium salt.

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

2004:546411 Document No. 141:94319 Dosage forms comprising a CETP inhibitor and a HMG-CoA reductase inhibitor. Friesen, Dwayne Thomas; Lorenz, Douglas Alan; Lyon, David Keith; Hancock, Bruno Caspar; Mcdermott, Timothy Joseph; Shanker, Ravi Mysore (Pfizer Products Inc., USA). PCT Int. Appl. WO 2004056359 A1 20040708, 194 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-IB6087 20031212. PRIORITY: US 2002-PV435345 20021220.

AB A dosage form comprises a solid **amorphous** dispersion comprising a cholesteryl ester transfer protein inhibitor and an acidic concentration-enhancing polymer, and an HMG-CoA reductase inhibitor. The solid **amorphous** dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid **amorphous** dispersion and the HMG-CoA reductase inhibitor are substantially sep. from one another in the dosage form. Thus, granulating the atorvastatin with excipients, then granulating the solid **amorphous** dispersion with excipients, followed by mixing the 2 granulations, provided improved atorvastatin stability.

L13 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
2004:546410 Document No. 141:94318 Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor. Friesen, Dwayne Thomas; Lyon, David Keith; Lorenz, Douglas Alan; Hancock, Bruno Caspar; Ketner, Rodney James; McDermott, Timothy Joseph; Shanker, Ravi Mysore (Pfizer Products Inc., USA). PCT Int. Appl. WO 2004056358 A1 20040708, 171 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-IB5861 20031209. PRIORITY: US 2002-PV435298 20021220.

AB A dosage form comprises (1) a solid **amorphous** dispersion comprising a cholesteryl ester transfer protein inhibitor and a neutral or neutralized acidic polymer and (2) an HMG-CoA reductase inhibitor. The dosage form provides improved chemical stability of the HMG-CoA reductase inhibitor. For example, crystalline atorvastatin was combined with an **amorphous** dispersion containing torcetrapib and hydroxypropyl Me cellulose. The stability of atorvastatin was improved relative to a control composition containing an acidic polymer.

L13 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
2002:754995 Document No. 137:268473 Porous drug matrices and methods of manufacture thereof. Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, Donald E.; Khattak, Sarwat; Randall, Greg (Acusphere Inc., USA). U.S. Pat. Appl. Publ. US 2002142050 A1 20021003, 20 pp., Cont.-in-part of U. S. 6,395,300. (English). CODEN: USXXCO. APPLICATION: US 2002-53929 20020122. PRIORITY: US 1999-PV136323 19990527; US 1999-PV158659 19991008; US 1999-433486 19991104.

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in **amorphous** form by preventing crystallization The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A solution of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the organic solution (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM. The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas.

```
=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   109.18     114.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -21.17     -21.17

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:33:05 ON 24 OCT 2005
```